GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Algernon Pharmaceuticals Inc (OTCPK:AGNPF) » Definitions » Gross Margin %

Algernon Pharmaceuticals (Algernon Pharmaceuticals) Gross Margin % : 0.00% (As of Nov. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Algernon Pharmaceuticals Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Algernon Pharmaceuticals's Gross Profit for the three months ended in Nov. 2023 was $0.00 Mil. Algernon Pharmaceuticals's Revenue for the three months ended in Nov. 2023 was $0.00 Mil. Therefore, Algernon Pharmaceuticals's Gross Margin % for the quarter that ended in Nov. 2023 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.


The historical rank and industry rank for Algernon Pharmaceuticals's Gross Margin % or its related term are showing as below:


AGNPF's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 59.4
* Ranked among companies with meaningful Gross Margin % only.

Algernon Pharmaceuticals had a gross margin of N/A% for the quarter that ended in Nov. 2023 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Algernon Pharmaceuticals was 0.00% per year.


Algernon Pharmaceuticals Gross Margin % Historical Data

The historical data trend for Algernon Pharmaceuticals's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Algernon Pharmaceuticals Gross Margin % Chart

Algernon Pharmaceuticals Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only - - - - -

Algernon Pharmaceuticals Quarterly Data
Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Algernon Pharmaceuticals's Gross Margin %

For the Biotechnology subindustry, Algernon Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Algernon Pharmaceuticals's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Algernon Pharmaceuticals's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Algernon Pharmaceuticals's Gross Margin % falls into.



Algernon Pharmaceuticals Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Algernon Pharmaceuticals's Gross Margin for the fiscal year that ended in Aug. 2023 is calculated as

Gross Margin % (A: Aug. 2023 )=Gross Profit (A: Aug. 2023 ) / Revenue (A: Aug. 2023 )
=0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0) / 0
=N/A %

Algernon Pharmaceuticals's Gross Margin for the quarter that ended in Nov. 2023 is calculated as


Gross Margin % (Q: Nov. 2023 )=Gross Profit (Q: Nov. 2023 ) / Revenue (Q: Nov. 2023 )
=0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0) / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Algernon Pharmaceuticals  (OTCPK:AGNPF) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Algernon Pharmaceuticals had a gross margin of N/A% for the quarter that ended in Nov. 2023 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Algernon Pharmaceuticals Gross Margin % Related Terms

Thank you for viewing the detailed overview of Algernon Pharmaceuticals's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Algernon Pharmaceuticals (Algernon Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
601 West Broadway, Suite 400, Vancouver, BC, CAN, V5Z 4C2
Algernon Pharmaceuticals Inc is a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis and chronic cough. The company's business model is capital efficient and strives to deliver maximum shareholder value. Algernon's approach to drug discovery is based on the concept of drug repurposing. It operates in two reportable segments: the development of repurposed therapeutic drugs in Canada, and the facilitation of the Company's drug candidates into off-label phase II clinical trials (humans) in Australia.

Algernon Pharmaceuticals (Algernon Pharmaceuticals) Headlines

From GuruFocus

Algernon Pharmaceuticals Announces Closing of Rights Offering

By sperokesalga sperokesalga 05-05-2023